Studies evaluating cardiovascular events solely in women are fewer in comparison with studies evaluating solely in men. Clinical data on the efficacy of antihypertensive, hypolipidemic or antidiabetic treatment are not many. Studies involving women were mainly focused on the influence of hormone replacement therapy on cardiovascular events. Some of these studies were challenged for their design. Many scientists believe that women included in these studies were too old and the period of time after the onset of menopause was too long. In this chapter, studies evaluating cardiovascular outcomes in women receiving hormone replacement therapy will be summarized. Hormone replacement therapy should not be recommended routinely for all postmenopausal women, as it is not clear if it presents cardioprotection and the detectable elevated risk of cardiovascular disease and breast cancer surpasses the benefits in asymptomatic women, by the time the newer data would become available.